Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

References

• Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Bidaoui G, Saleh M, et al. Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome. Clin Hematol Int. 2023. doi:10.1007/s44228-023-00041-x
   Google Scholar
• Dinardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Zhu LX, Chen RR, Wang LL, et al. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Support Care Cancer. 2022;30(8):7031–7038. doi:10.1007/s00520-022-07126-y
   PubMed Web of Science ®Google Scholar
• Morsia E, Mccullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: mayo clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521. doi:10.1002/ajh.25978
   PubMed Web of Science ®Google Scholar
• Gangat N, Johnson I, Mccullough K, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022;107(10):2501–2505. doi:10.3324/haematol.2022.281214
   PubMed Web of Science ®Google Scholar
• Todisco E, Papayannidis C, Fracchiolla N, et al. AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992–1004. doi:10.1002/cncr.34608
   PubMed Web of Science ®Google Scholar
• Vachhani P, Flahavan EM, Xu T, et al. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist. 2022;27(11):907–918. doi:10.1093/oncolo/oyac135
   PubMed Web of Science ®Google Scholar
• Pratz KW, Dinardo CD, Selleslag D, et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Blood. 2020;136(Supplement 1):51–53. doi:10.1182/blood-2020-134832
   Google Scholar
• Feld J, Tremblay D, Dougherty M, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed/refractory advanced myeloid malignancies. Hemasphere. 2021;5(4):e549. doi:10.1097/HS9.0000000000000549
   PubMed Web of Science ®Google Scholar
• Vachhani P, Abbas JA, Flahavan EM, et al. Real world treatment patterns and outcomes of venetoclax (ven) and hypomethylating agents (HMA) in patients with newly diagnosed acute myeloid leukemia (AML) in the United States. Blood. 2021;138(Supplement 1):2290–2290. doi:10.1182/blood-2021-147851
   PubMedGoogle Scholar
• Willekens C, Chraibi S, Decroocq J, et al. Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia. Blood. 2022;140(Supplement 1):537–538. doi:10.1182/blood-2022-165464
   Google Scholar
• Gershon A, Ma E, Xu T, et al. Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately us community setting. Clin Lymphoma Myeloma Leuk. 2023;23(5):e222–e231. doi:10.1016/j.clml.2023.02.002
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• De Bellis E, Imbergamo S, Candoni A, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leuk Res. 2022;114:106803. doi:10.1016/j.leukres.2022.106803
   PubMed Web of Science ®Google Scholar
• Garciaz S, Hospital MA, Alary AS, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022;14(8). doi:10.3390/cancers14082025
   PubMed Web of Science ®Google Scholar
• Apel A, Moshe Y, Ofran Y, et al. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021;96(7):790–795. doi:10.1002/ajh.26190
   PubMed Web of Science ®Google Scholar
• Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565–5573. doi:10.1182/bloodadvances.2021005538
   PubMed Web of Science ®Google Scholar
• Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564. doi:10.1182/bloodadvances.2020003734
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803. doi:10.1182/blood.2019003988
   PubMed Web of Science ®Google Scholar
• Weng G, Zhang Y, Yu G, et al. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med. 2023;293(3):329–339. doi:10.1111/joim.13581
   PubMed Web of Science ®Google Scholar
• Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536–551. doi:10.1158/2159-8290.CD-19-0710
   PubMed Web of Science ®Google Scholar
• Aiba M, Shigematsu A, Suzuki T, et al. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102(3):541–546. doi:10.1007/s00277-023-05102-y
   PubMed Web of Science ®Google Scholar
• Mirgh S, Sharma A, Shaikh M, et al. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy – novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290–302.
   PubMed Web of Science ®Google Scholar